Bob Wildin, M.D., chief of the Genomic Healthcare Branch at the National Human Genome Research Institute (NHGRI), leads a team of health and education professionals dedicated to advancing the integration of genomic medicine into general healthcare practice. As a medical geneticist, Dr. Wildin is particularly interested in increasing the efficiency and effectiveness of clinical use of genetics and genomics, including the development of electronic data transmission, storage, and useful presentation standards for clinical genetic and genomic information.
In addition to a primary role supporting the mission of NHGRI, Dr. Wildin serves as co-chair of the Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC), and represents NHGRI on the Institute of Medicine's Roundtable on Translating Genomic-Based Research for Health. He participates in education, information-sharing, and policy advancement activities with other health-related federal agencies, including the FDA, CMS, HRSA and others. In late 2015, Dr. Wildin will practice clinical genetics in both community and research settings in order to better inform the research and policy communities on current challenges to genomic medicine implementation.
Dr. Wildin joined NHGRI in November 2014 after nearly 10 years as an independent clinical geneticist contracting with non-academic healthcare systems in Oregon and Idaho for part-time clinical services, often as the sole general genetics physician provider. During that period he also offered independent biomedical informatics consulting services and authored software designed to increase the efficiency of online genetics information use by medical geneticists in the clinic.
Prior to that, Dr. Wildin served as faculty at academic medical centers in Washington, Texas and Oregon. He staffed clinics, taught medical and graduate students, directed a medical genetics residency program, and co-directed a clinical molecular diagnostic laboratory. He also directed research laboratories studying the causes of rare human genetic disorders, and explored pre-clinical treatment approaches. Conditions studied included Nephrogenic Diabetes Insipidus (NDI) and"Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked (IPEX).
Dr. Wildin received his bachelor's degree in life sciences from the Massachusetts Institute of Technology and his M.D. from the University of California San Francisco. He completed his pediatric residency and a medical genetics fellowship at the University of Washington and Children's Hospital Medical Center in Seattle. He obtained board certification in pediatrics and in medical genetics (clinical), and maintains current status in the latter.
Last Updated: August 6, 2015